Oh, The Places Dermatology Will Go in 2024!
The Dermatology Digest
FEBRUARY 8, 2024
“It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.” Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., Upadacitinib’s (Rinvoq, AbbVie) 5-yr safety data show that it is REALLY SAFE and effective in AD, and abrocitinib (Cibinqo, Pfizer) is safe as well.” What’s next? “We
Let's personalize your content